Correspondence to: Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients
- PMID: 35218045
- DOI: 10.1111/all.15185
Correspondence to: Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients
Comment in
-
Reply to: "Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients".Allergy. 2022 Jul;77(7):2269-2270. doi: 10.1111/all.15285. Allergy. 2022. PMID: 35770817 Clinical Trial. No abstract available.
Comment on
-
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.Allergy. 2022 Mar;77(3):897-906. doi: 10.1111/all.15071. Epub 2021 Sep 6. Allergy. 2022. PMID: 34460948 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Guttman-Yassky E, Renert-Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients. Allergy. 2021;10.1111/all.15071
-
- Paul WE. Interleukin 4: signalling mechanisms and control of T cell differentiation. Ciba Found Symp. 1997;204:208-216. 10.1002/9780470515280.ch14
-
- Wei J, Duramad O, Perng OA, Reiner SL, Liu Y-J, Qin FX-F. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2007;104(46):18169-18174. 10.1073/pnas.0703642104
-
- Ito T, Kageyama R, Nakazawa S, Honda T. Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata. Exp Dermatol. 2020;29(8):726-732. 10.1111/exd.14129
-
- Khan MA. Regulatory T cells mediated immunomodulation during asthma: a therapeutic standpoint. J Transl Med. 2020;18(1):456. 10.1186/s12967-020-02632-1
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources